Auna SA

$4.41 ▼ -2%
2026-06-06 06:39:01

Explore Auna SA stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.

Market Cap
$94.88 M
Current Price
$4.41
52W High / Low
$6.85 / $4.09
Stock P/E
16.19
Book Value
$6.29
Dividend Yield
ROCE
14.53%
ROE
4.14%
Face Value
EPS
$0.27
Exp Qtr EPS
Sector
Healthcare

AUNA — Monthly Price History

Adjusted close price  ·  Hover to see price & month

Pros

  • Efficient use of capital employed.
  • Valuation is not stretched on P/E basis.

Cons

  • Return on equity is on the weaker side.
  • Leverage is relatively high.
  • Current ratio suggests tighter short-term liquidity.
  • Net margin is relatively low.

Sift Stocks

S.No. Name Price P.E. Market Cap Div Yld % ROCE ROE 52Week High/ Low Book Value
1. Tenet Healthcare Corporation $162.06 8.23 $14.01 B 13.64% 40.55% $247.21 / $146.6 $48.53
2. DaVita Inc. $192.16 15.81 $12.36 B 14.02% 181.22% $202.69 / $101 $1.5
3. Encompass Health Corporation $104.01 16.94 $10.32 B 0.76% 16.84% 25.35% $127.99 / $92.77 $24.38
4. The Ensign Group, Inc. $170.3 26.94 $9.79 B 0.16% 9.31% 16.64% $218 / $134.79 $38.42
5. Universal Health Services, Inc. $145.17 5.68 $8.64 B 0.56% 16.23% 21.02% $246.33 / $140.76 $119.15
6. PACS Group, Inc. $37.01 24.33 $5.93 B 6.76% 26.63% $43.08 / $7.5 $6.05
7. Chemed Corporation $441.59 22.45 $5.83 B 0.56% 27.27% 25.33% $565.66 / $365.21 $71.43

Quarterly Results

Figures shown in M / B

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Sales1.13 B1.12 B1.09 B1.04 B1.06 B1.13 B
Operating Profit153.27 M160 M172 M145.56 M198.16 M199.65 M
Net Profit-68.39 M48 M81.98 M35.43 M21.96 M97.89 M
EPS in Rs-2.271.592.721.180.733.25

Profit & Loss

Figures shown in M / B

2025202420232022
Sales4.39 B4.39 B3.88 B2.45 B
Operating Profit631.27 M746.18 M545.73 M243.14 M
Net Profit97.61 M110.27 M-253.92 M-85.61 M
EPS in Rs3.243.66-8.43-2.84

Balance Sheet

Figures shown in M / B

2025202420232022
Total Assets7.3 B7.08 B7.69 B6.59 B
Total Liabilities5.53 B5.46 B5.91 B5.04 B
Equity1.6 B1.48 B1.47 B1.06 B
Current Assets1.84 B1.7 B1.55 B1.2 B
Current Liabilities1.67 B1.95 B1.69 B2.85 B

Cash Flow

Last available yearly cash flow history

2025202420232022
Operating CF662.5 M668.5 M582.41 M162.64 M
Investing CF-80.25 M-236.82 M-173.15 M-3.21 B
Financing CF-487.1 M-418.12 M-370 M3.13 B
Free CF517.82 M526.65 M417.25 M10.67 M
Capex-144.68 M-141.85 M-165.16 M-151.97 M

5Y Margin & Growth History

Last 5 years of annual financial statement data.

2024202320222021
Revenue Growth %13.16%58.1%
Earnings Growth %143.43%-196.62%
Profit Margin %2.51%-6.55%-3.49%
Operating Margin %17.01%14.08%9.92%
Gross Margin %39.34%37.03%35.88%
EBITDA Margin %20.22%16.7%12.2%

Dividend & Split History

Latest dividend payments and stock split events.

Dividend History

No dividend history available.

Stock Splits

No stock split history available.

Shareholding Pattern

Shares and value shown in M / B

Holder Name Type Shares Value % Out Report Date
iShares Trust-iShares MSCI Peru and Global Exposure ETF Mutual Fund 0.95 M $5.39 M 0.03% 2026-01-31
Global Opportunities Portfolio Mutual Fund 0.25 M $1.41 M 0.01% 2026-01-31
SPDR INDEX SHARES Fd.S-State Street SPDR S&P Emerging Markets Small Ca Mutual Fund 0.02 M $0.11 M 0% 2026-01-31
TEACHER RETIREMENT SYSTEM OF TEXAS Institutional 1.88 M $10.66 M 0.06% 2025-12-31
Fiera Capital Corporation Institutional 0.91 M $5.18 M 0.03% 2025-12-31
Blackrock Inc. Institutional 0.6 M $3.39 M 0.02% 2025-12-31
SEI INSTITUTIONAL INVESTMENTS TRUST-SIIT EMERGING MARKETS EQUITY FUND Mutual Fund 0.44 M $2.51 M 0.01% 2025-12-31
Verde Servicos Internacionais S.a. Institutional 0.32 M $1.83 M 0.01% 2025-12-31
Morgan Stanley Institutional 0.27 M $1.51 M 0.01% 2025-12-31
Marshall Wace LLP Institutional 0.16 M $0.92 M 0.01% 2025-12-31
Citadel Advisors Llc Institutional 0.13 M $0.71 M 0% 2025-12-31
Renaissance Technologies, LLC Institutional 0.11 M $0.64 M 0% 2025-12-31
UBS Group AG Institutional 0.09 M $0.53 M 0% 2025-12-31
Goldman Sachs Group Inc Institutional 0.07 M $0.41 M 0% 2025-12-31

Frequently Asked Questions — Auna SA

Will Auna SA stock hit $5 in 2026?

Auna SA (AUNA) is currently trading at $4.41, with a 52-week range of $4.09 to $6.85. Reaching the $5 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.

Wall Street analysts currently have a consensus price target of $7.2 for Auna SA, with a Buy rating, and the most bullish analysts see the stock reaching as high as $9.0. Whether Auna SA can reach $5 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.

Historically, AUNA has delivered a -33.6% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the AUNA Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.

Is Auna SA stock worth buying at $4.41?

Whether Auna SA (AUNA) is worth buying at $4.41 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:

Valuation: Auna SA trades at a Price-to-Earnings (P/E) ratio of 16.2x, which can be compared against other Healthcare companies to assess whether the stock is expensive or attractively priced relative to its peers.

Profitability & efficiency: Auna SA has a Return on Capital Employed (ROCE) of 14.5%, which reflects modest capital efficiency. Its Return on Equity (ROE) stands at 4.1%.

Financial health: The Debt-to-Equity ratio of 218.74 indicates a higher degree of financial leverage — investors should monitor debt servicing capacity.

Analyst view: The Wall Street consensus recommendation for AUNA is currently Buy, with a mean price target of $7.2 based on 7 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.

What is the analyst price target for Auna SA (AUNA) in 2026?

As of 2026, Wall Street analysts have set a consensus (mean) price target of $7.2 for Auna SA (AUNA), aggregated from 7 analyst ratings. The overall analyst recommendation is Buy.

The price target range spans from $6.0 on the bearish end to $9.0 on the most optimistic projection, with a median target of $6.9. This wide range reflects differing views on Auna SA's growth prospects, competitive positioning, and macroeconomic sensitivity.

It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the AUNA analysis page on StockSifting.

Is Auna SA overvalued at a P/E ratio of 16.2x?

Auna SA (AUNA) currently has a Price-to-Earnings (P/E) ratio of 16.2x, meaning investors are paying $16.2 for every $1 of the company's trailing twelve-month earnings. Whether this makes the stock overvalued depends on several contextual factors:

Sector context: The Healthcare sector tends to command higher valuation multiples when growth expectations are elevated. A 16.2x P/E falls within a moderate range, reflecting reasonable market confidence in Auna SA's earnings outlook.

Growth-adjusted valuation: A P/E ratio in isolation can be misleading. Fast-growing companies often deserve higher P/E multiples because their future earnings are expected to rise significantly. A more complete picture comes from looking at the PEG ratio (P/E divided by earnings growth rate) — a PEG below 1 is often considered undervalued, while above 2 may signal overvaluation. Auna SA's ROCE of 14.5% suggests it has moderate capital returns.

Additional metrics to review: P/E is just one lens. Compare it alongside the Price-to-Book (P/B) ratio, EV/EBITDA, Price-to-Sales, and free cash flow yield for a more complete valuation picture. View all of AUNA's valuation ratios on StockSifting's ratios section. Valuation is subjective and context-dependent — this is not investment advice.

What will Auna SA stock be worth in 2029?

Projecting Auna SA (AUNA)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.

Based on AUNA's historical 5-year Compound Annual Growth Rate (CAGR) of -33.6%, if that rate of growth were to continue, the stock could reach approximately $1 by 2029 — up from its current price of $4.41. This projection assumes the historical CAGR holds, which depends on Auna SA sustaining its revenue growth, maintaining profit margins, and the market continuing to reward it at a similar valuation multiple.

In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.

You can model different scenarios — conservative, base, and bull case — using the AUNA Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.